Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06947044 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Biomarkers in Patients With Anemia-Induced Thrombocytopenic Bleeding

Study acronym: BAIT
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary endpoints: details revised at 1 of 5 entries Enrollment closed, study ongoing · Primary completion date changed from estimate of Nov 1, 2026 to Aug 31, 2026 · Completion pushed from Nov 1, 2026 to Feb 1, 2027 · 3 more Show 6 more changesShow less
    • Enrollment closed, study ongoing
    • Primary completion date changed from estimate of Nov 1, 2026 to Aug 31, 2026
    • Completion pushed from Nov 1, 2026 to Feb 1, 2027
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints: details revised at 1 of 3 entries
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This pilot study aims to gather preliminary evidence on how different hemoglobin levels impact blood biomarkers related to bleeding. The feasibility of conducting a future larger clinical trial will also be assessed. Red blood cell transfusions are part of the standard of care for patients with leukemia. This study evaluates two transfusion strategies: one that maintains hemoglobin levels above the standard-of-care threshold, reflecting current routine practice; and another that maintains hemoglobin levels above 110 g/L, which is closer to the normal hemoglobin range. The normal hemoglobin range is 120-160 g/L for females and 140-180 g/L for males. Raising hemoglobin levels closer to normal values may reduce bleeding risk.
Trial Details
NCT Number NCT06947044
Lead Sponsor Donald Arnold
Conditions Acute Leukemia, Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukaemia
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov